Acrivon’s AI-Designed Cancer Drug Shows Promise in Hard-to-Treat Tumors

WATERTOWN, MA – August 05, 2026 – In a significant development for precision oncology, Acrivon Therapeutics today announced that its investigational drug, ACR-2316, is advancing into a randomized dose expansion phase of its ongoing clinical trial. The decision is backed by encouraging early data showing the drug has a favorable safety profile and achieves durable clinical activity, even in heavily pretreated cancer patients. Most notably, several lung cancer patients have remained on the single-agent therapy for over a year, a remarkable outcome for a population with few remaining options.

This milestone is more than just a step forward for a promising compound; it represents a powerful validation of Acrivon's proprietary AI-driven discovery platform and a strategic alignment with modern, patient-centric approaches to drug development championed by the FDA.

The Power of a Predictive Platform

At the heart of Acrivon's strategy is its Generative Phosphoproteomics AP3 platform, a sophisticated system designed to move beyond the limitations of traditional drug discovery. Where many approaches focus on a single biological target, Acrivon's platform analyzes the complex web of protein interactions inside a living cancer cell. By measuring how a drug candidate regulates thousands of phosphoproteins simultaneously, AP3 creates a detailed map of a compound's true intracellular effects, allowing for what the company calls “rational drug design.”

ACR-2316 was born from this process. It is a novel inhibitor designed to block two key cell cycle regulators, WEE1 and PKMYT1. While other companies have pursued WEE1 inhibitors, research has shown that cancer cells can develop resistance by activating a compensatory pathway involving MYT1. By designing a dual inhibitor from the ground up, Acrivon aimed to block this escape route and induce more potent and durable cancer cell death.

“We rationally designed ACR-2316 using AP3 to overcome the resistance mechanisms that limit efficacy of single-target WEE1 and PKMYT1 inhibition, hence enabling potent tumor cell death,” said Peter Blume-Jensen, M.D., Ph.D., CEO and co-founder of Acrivon. The early clinical data suggests this hypothesis is bearing fruit. The platform not only guided the drug’s molecular design but also predicted which tumor types would be most sensitive, including forms of lung cancer not previously shown to respond to single-agent WEE1 inhibitors.

A Glimmer of Hope for Patients with Few Options

The true measure of any new therapy is its impact on patients. The initial results from the ACR-2316 Phase 1/2 study, while early, are compelling. In a group of seven heavily pretreated lung cancer patients—spanning small cell, squamous non-small cell, and adenocarcinoma—the drug achieved a disease control rate of 86%, including two partial responses. For patients who have often exhausted multiple prior lines of therapy, stabilizing the disease is a meaningful clinical victory.

The durability of these responses is particularly noteworthy. The company reported that three of these lung cancer subjects have remained on treatment for over one year, a testament to both the drug's sustained activity and its tolerability. This is a significant signal in cancers like SCLC, a notoriously aggressive disease where long-term survival remains tragically low despite recent advances.

The dose expansion will now formally evaluate ACR-2316 in biomarker-selected populations across several high-need cancers, including multiple types of lung cancer, endometrial cancer (where partial responses were also seen), cervical cancer, and esophago-gastric junction cancer. These are all areas where new, effective therapies are desperately needed for patients who have relapsed or become resistant to standard care.

Redefining 'Optimal' with FDA's Project Optimus

Acrivon’s clinical strategy is as forward-thinking as its discovery science. The trial design for ACR-2316 explicitly adheres to the principles of the FDA’s Project Optimus, a major initiative to reform how oncology drug doses are selected. For decades, the standard was to find the “maximum tolerated dose” (MTD), a relic of chemotherapy development that often resulted in significant toxicity for patients receiving modern targeted therapies.

Project Optimus encourages a more nuanced approach: identifying the dose that provides the optimal balance of benefit and risk. Instead of simply escalating to the highest dose patients can bear, Acrivon will now randomly assign patients to either a 120 mg or 160 mg daily dose (on a 3 days on, 4 days off schedule) to determine which provides the best overall outcome. This method aims to improve quality of life and ensure the drug is used most effectively from the outset.

This patient-centric approach is enabled by ACR-2316's safety profile. “ACR-2316 has demonstrated a favorable safety profile in dose escalation, with adverse events limited primarily to transient, mechanism-based hematological events, mainly neutropenia, and a notable absence of non-hematological adverse events,” said Mansoor Raza Mirza, M.D., chief medical officer of Acrivon. This clean profile gives the company the flexibility to explore multiple active doses without exposing patients to undue harm, perfectly aligning with the FDA's vision for the future of cancer drug development.

Differentiating in a Competitive Field

While WEE1 inhibition is a validated target, the clinical landscape is fraught with challenges. Other WEE1 inhibitors, such as adavosertib, have shown activity but have also been hampered by toxicities that have complicated their development, particularly in combination regimens. Acrivon's ability to demonstrate potent, single-agent activity with a manageable safety profile is a key differentiator.

The dual WEE1/PKMYT1 mechanism appears central to this success. By hitting two nodes in the cell cycle checkpoint pathway, ACR-2316 may be creating a more profound and inescapable vulnerability for cancer cells, particularly those with common mutations like TP53 loss. This robust mechanism could explain the durable responses and its activity in tumor types that have been historically resistant to this class of agents.

As the randomized dose expansion study progresses, the oncology community will be watching closely for further data that could solidify ACR-2316's role in the future of cancer therapy.